BeyondSpring Inc. (BYSI)
NASDAQ: BYSI · IEX Real-Time Price · USD
2.130
-0.140 (-6.17%)
At close: Apr 26, 2024, 4:00 PM
2.120
-0.010 (-0.47%)
After-hours: Apr 26, 2024, 7:36 PM EDT
BeyondSpring Revenue
BeyondSpring had revenue of $1.55M in the twelve months ending June 30, 2023, with 29.92% growth year-over-year. In the year 2022, BeyondSpring had annual revenue of $1.35M.
Revenue (ttm)
$1.55M
Revenue Growth
+29.92%
P/S Ratio
53.61
Revenue / Employee
$21,233
Employees
73
Market Cap
83.10M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 1.35M | - | - |
Dec 31, 2021 | 1.35M | 1.17M | 650.56% |
Dec 31, 2020 | 180.00K | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
The Oncology Institute | 324.24M |
Burning Rock Biotech | 75.80M |
Allurion Technologies | 53.47M |
ProPhase Labs | 44.38M |
Armata Pharmaceuticals | 4.53M |
Abeona Therapeutics | 3.50M |
Genelux | 170.00K |
BYSI News
- 4 weeks ago - BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer - GlobeNewsWire
- 3 months ago - BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K - GlobeNewsWire
- 4 months ago - BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements - GlobeNewsWire
- 6 months ago - BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitors - GlobeNewsWire
- 6 months ago - SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors - GlobeNewsWire
- 7 months ago - BeyondSpring and Leading Cancer Center to Present Poster at SITC's 38th Annual Meeting - GlobeNewsWire
- 8 months ago - BeyondSpring to Participate in the R.W. Baird's 2023 Global Healthcare Conference - GlobeNewsWire
- 1 year ago - BeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual Meeting - GlobeNewsWire